This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1.
Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available.
One case, stated as one case.
Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability.
Stating my assumptions rather than smuggling them in.
Picking up post #32: that is the part I would want checked first.
Washout after stopping takes roughly the same four to five half-lives as reaching steady state. A month after the last dose is not the same as none.
Adding the measurement that post #36 says would settle it.
Bioavailability: oral semaglutide has low bioavailability (roughly 1%) due to peptide instability. That is why the oral dose (14 mg) is so much larger than the injectable dose. Comparing them by mass is meaningless.
Building on post #36 rather than restating it.
The accumulation ratio for weekly dosing with a week-long half-life is around two, which is why the concentration after several doses is roughly double the concentration after the first.
Post #39 put the caveat in the right place and I want to underline it.
A missed weekly dose perturbs a slowly moving average rather than creating a trough. That is the pharmacokinetic reason the labelling does not recommend doubling.
Someone will know this better than I do and I hope they say so.
Half-life: semaglutide ≈ 165–184 hours (about a week). Tirzepatide ≈ 5 days. Liraglutide ≈ 13 hours. The half-life determines how much accumulation happens at steady state and how long it takes to clear after stopping.
The general case is well covered; this is the awkward specific one.
Narrowing post #39, because the general version has more than one answer.
A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.
I looked this up rather than remembered it, which is the right order.
Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.
Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the number.
The right answer here may simply be that it has not been measured.
Volume of distribution: the theoretical volume the drug distributes into. For albumin-binding compounds, volume is reduced compared to drugs that do not bind protein. That is relevant to understanding how much free drug is available.
I would want the raw data before agreeing with my own summary of it.
Metabolism for peptide drugs is proteolytic rather than hepatic in the usual sense, which is why the cytochrome interaction questions that dominate small-molecule pharmacology mostly do not apply.
One more caveat and then I will stop qualifying: the sample selected itself.
Where I part company with post #43, and it is a narrow parting.
Dose proportionality across the studied range means dose arithmetic behaves the way you would naively expect. It is worth checking whether it holds for a given compound rather than assuming.
Steady state is approached in roughly four to five half-lives. For a compound with a week-long half-life that is four to five weeks, which is where the escalation interval in the trials comes from.
Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability.
Body weight affects volume of distribution and therefore exposure at a fixed dose. Whether that translates into a dosing implication depends on the width of the therapeutic window.
I have said this before in a thread nobody could find, so it is worth repeating.
This follows post #51 rather than contradicting it.
Accumulation at steady state: with a week-long half-life, steady-state concentration is reached around 4 to 5 half-lives (about 4 to 5 weeks). Before that, concentration is rising with each dose. The clinical implication: escalating before 4 weeks means escalating before steady state.
Worth separating two things that post #52 runs together.
A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.
The short version is the first sentence; the rest is why.
Individual variation: people vary in how quickly they absorb, distribute, metabolise, and excrete these compounds. That variation is partly genetic and partly due to individual biology (gut motility, kidney and liver function). It explains why two people on the same dose have different response magnitudes.
The general answer and the answer for your case may diverge here.
On post #56 — agreed on the reasoning, with one qualification.
Fasting requirement for oral semaglutide: food and large fluid volumes reduce absorption. The fasting window (30 minutes before and 30 minutes after) is designed to maximise absorption. Violating it measurably reduces exposure.
Everything in post #56 holds. The case it does not cover is the one I have.
Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the number.